First order 60% off · Free consultation · Free cancellation
Free consult
GIP / GLP-1 · Medical Weight Loss

Mounjaro

Tirzepatide · Zepbound

Medical science
for your ideal self.

10,000+Consults
96.4%Satisfaction
¥0Consult fee
¥17,000~*1
/ month (¥18,700~ tax incl.)
Start a free LINE consultation

Available 24/7 / Same-day shipping

*1 Monthly cost (before tax) when the first-order coupon is applied to the 6-month subscription plan. See Pricing for details.
*2 Self-pay (not covered by Japan's public health insurance).

Contents
About Mounjaro Results Pricing All treatments How it works Why Mimipo Our doctor FAQ

Who it's for

Want to lose weight
fast

Want to drop kilos
for good

Struggling with
dieting

MEDICAL DIET

Science-backed support for a body that loses weight naturally

How Mounjaro works: curbs appetite, prevents blood-sugar spikes, and supports visceral fat burning — GIP + GLP-1 targets two hormones at once.

Mounjaro (generic name: tirzepatide) is the world's first injectable that acts on both GIP and GLP-1 hormones simultaneously. The same active ingredient is also marketed as Zepbound — FDA-approved for obesity in the U.S. (2023) and approved in Japan in December 2024.

Start anytime, anywhere
with online care
available 24/7

Licensed Japanese physician ready for your online consultation Licensed MD
Patient consulting with a doctor from home on her smartphone You, from home

Chat with a Japanese-licensed physician on LINE — from anywhere, any time.

3 easy steps

1

Book your consultation on LINE

Book any time, 24/7

2

Online consultation

~5 min on your phone · ¥0 consult fee

3

Delivered to your door

Same-day shipping · arrives in 1–2 days

Consultations completed

10,000+

Experienced physicians build
a plan tailored to you.

Consultations & follow-ups
are always ¥0

Reach out any time.
Follow-up consultations are always free.

Patient satisfaction

96.4%

Message us on LINE any time —
first-timers feel at ease.

Real patient results

*Individual results vary.

Before Case 1 before Mounjaro treatment
▶
After Case 1 after 3 months of Mounjaro treatment
Mounjaro3 months
-8.2 kg

Woman, 30s / 76 kg → 67.8 kg

Before Case 2 before Mounjaro treatment
▶
After Case 2 after 6 months of Mounjaro treatment
Mounjaro6 months
-12.5 kg

Woman, 40s / 82 kg → 69.5 kg

Before Case 3 before GLP-1 treatment
▶
After Case 3 after 4 months of GLP-1 treatment
Ozempic4 months
-6.8 kg

Woman, 20s / 65 kg → 58.2 kg

*Treatment outcomes vary between individuals. Photos are published with patient consent.
*Some cases combine medication with diet and exercise coaching.

Start a free LINE consultation

A doctor will propose the plan that fits you.

Don't like needles? No problem.

The needle is about 1/4 the thickness of a standard blood-draw needle.

Virtually painless. Just press a button, once a week.

Pricing

A full menu, tailored to you.

Mounjaro (Tirzepatide)

GIP/GLP-1 injection · ★ Most popular · Zepbound's active ingredient

Appetite control Blood-sugar control Visceral-fat burning
¥17,000~ /mo (tax incl. ¥18,700~)
First-time campaign price / Tirzepatide 2.5 mg × 4 pens
See full pricing
2.5 mg
(4 pens/mo)		 Monthly 3-month plan 6-month plan
Campaign
price
¥19,800/mo
First order total ¥19,800
From 2nd order
Total ¥33,000
¥19,250/mo
First order total ¥57,750
From 2nd order
Total ¥94,050
¥18,700/mo
First order total ¥112,200
From 2nd order
Total ¥178,200

*All prices include tax.
*A ¥550 shipping fee (tax incl.) applies separately.
*Reflects the first-time-buyer campaign price.

Chat on LINE ＞

Other injectable treatments

OzempicGLP-1 (semaglutide)
¥20,350~(tax incl.)

*Prescription subject to physician review.
*A ¥550 shipping fee (tax incl.) applies separately.

Start a free LINE consultation

Not sure which plan? Message us anyway.

Other prescriptions

Oral medications

RybelsusOral GLP-1 (semaglutide)
¥7,040~/mo (tax incl.)
ForxigaSGLT2 inhibitor (dapagliflozin)
¥2,967~/mo (tax incl.)
CanagluSGLT2 inhibitor (canagliflozin)
¥3,867~/mo (tax incl.)
MetforminBiguanide class
¥1,584~/mo (tax incl.)

Diet Kampo (Japanese herbal medicine)

Bofu-tsusho-san防風通聖散
¥4,224~/mo (tax incl.)
Boi-ogi-to防已黄耆湯
¥4,840~/mo (tax incl.)

*Prescription subject to physician review.

Demand has been exceptionally strong.

If you're interested, please reach out soon.

Our medical advisor

Portrait of Dr. Yutaka Shionoiri, M.D., Mimipo Medical Advisor

Dr. Yutaka Shionoiri, M.D.

Mimipo Medical Advisor
Board Chairman, Shionoiri Internal Medicine (Medical Corporation)

At Mimipo, we aim to ease the concerns and worries of every patient. We connect you online with physicians at our partner clinics so consultations are available anywhere, anytime. Our service is open year-round, from early morning to late at night — even on busy days, you can fit a consultation into a short break. Because it's natural to feel uneasy when you can't see a doctor face-to-face, Mimipo also provides thorough follow-up after your consultation. If anything concerns you, please feel free to reach out.

View career & qualifications

Career history

1995 — Graduated, Kitasato University School of Medicine
1996 — Resident, The University of Tokyo Hospital
1997 — Internal Medicine Resident, Kanto Central Hospital
1998 — Internal Medicine, Tokyo Metropolitan Geriatric Hospital (now Tokyo Metropolitan Geriatric Medical Center)
1998 — Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo
2000 — Department of Reproduction, Development and Aging, Graduate School of Medicine, The University of Tokyo
2000 — RIKEN Brain Science Institute (Wako City)
2001 — Department of Geriatric Medicine, The University of Tokyo Hospital
2007 — Yokohama Sakae Kyosai Hospital
2020 — Shionoiri Internal Medicine
2022 — Shionoiri Internal Medicine (Medical Corporation)
2023 — Director, Shionoiri Internal Medicine (Medical Corporation)
2024 — Board Chairman, Shionoiri Internal Medicine (Medical Corporation)

Clinical focus

General internal medicine, geriatrics, anti-aging medicine, arteriosclerotic diseases, metabolic and endocrine disorders, hypertension, kidney disease, allergic disorders, infectious diseases, respiratory conditions, and more.

Frequently asked questions

Are there side effects?
The most common are gastrointestinal symptoms (nausea, diarrhea, constipation, etc.). They usually appear early in treatment and subside over time. Talk to your doctor; we can adjust the dose if needed.
Is Mounjaro the same as Zepbound?
Both contain the same active ingredient, tirzepatide, made by Eli Lilly. Mounjaro is the brand name approved for type 2 diabetes; Zepbound is the brand approved for obesity (FDA, 2023; approved in Japan in December 2024). The molecule and mechanism are identical.
What's the difference between Mounjaro, Tirzepatide, and Zepbound?
Tirzepatide is the generic (active ingredient) name. Mounjaro and Zepbound are brand names for the same tirzepatide molecule, marketed by Eli Lilly for different indications.
Will I regain the weight?
During treatment, many patients build the habit of feeling satisfied with smaller portions. That habit often carries over after you stop.
Does the injection hurt?
The needle is about 1/4 the thickness of a standard blood-draw needle. It's a one-touch pen — just press a button.
When will it arrive?
Orders paid before 6 pm ship the same day and arrive within 1–2 days.
Is this covered by insurance?
No — this is self-pay care (not covered by Japan's public health insurance). We accept credit cards and bank transfer.
Can I cancel my subscription?
Yes, any time, free of charge. Just message us on LINE.

This is where your
weight-loss journey changes.

Start with a free consultation.
A doctor will propose a plan tailored to you.

Start a free LINE consultation
✓ ¥0 consultation ✓ Same-day shipping ✓ 24/7 support

About the use of unapproved medications

The medications below are all approved by Japan's Ministry of Health, Labour and Welfare (MHLW) for type 2 diabetes. However, their use for obesity treatment is not approved in Japan.

Mounjaro
Ozempic
Rybelsus
Forxiga
Canaglu
Metformin
Kampo
Mounjaro (tirzepatide) — GIP/GLP-1 receptor agonist injection
Approval in JapanApproved for type 2 diabetes. Use for obesity is not approved.
Same ingredientZepbound, which contains the same active ingredient (tirzepatide), was approved in Japan in December 2024 for obesity treatment.
Overseas approvalFDA-approved for type 2 diabetes. Approved for obesity under the brand name Zepbound in 2023.
SourceImported individually by partner-clinic physicians, in accordance with MHLW's official procedure.
Side effectsGI symptoms (nausea, vomiting, diarrhea, constipation, abdominal pain), hypoglycemia, indigestion, headache/dizziness, injection-site reactions.
Relief SystemUse for obesity is not covered by Japan's Adverse Drug Reaction Relief System.
Ozempic (semaglutide) — GLP-1 receptor agonist injection
Approval in JapanApproved for type 2 diabetes. Use for obesity is not approved.
Same ingredientWegovy (same active ingredient, semaglutide) was approved in Japan in February 2024 for obesity treatment.
Overseas approvalFDA-approved for type 2 diabetes.
SourceImported individually by partner-clinic physicians.
Side effectsGI symptoms, hypoglycemia, loss of appetite, injection-site reactions, gallstones (rare).
Relief SystemUse for obesity is not covered.
Rybelsus (semaglutide) — Oral GLP-1 receptor agonist
Approval in JapanApproved for type 2 diabetes. Use for obesity is not approved.
Same ingredientWegovy (injectable) shares the same active ingredient and is approved in Japan for obesity. The oral form is not approved for obesity.
Overseas approvalFDA-approved for type 2 diabetes.
Side effectsGI symptoms, GI disorders, hypoglycemia, loss of appetite, headache.
Relief SystemUse for obesity is not covered.
Forxiga (dapagliflozin) — SGLT2 inhibitor
Approval in JapanApproved for diabetes, chronic kidney disease, and heart failure. Use for obesity is not approved.
Same ingredientNo same-ingredient obesity-indication drug is approved in Japan.
Overseas approvalFDA-approved for type 2 diabetes.
Side effectsUrinary-tract infection, genital infection, dehydration, hypoglycemia, renal function changes, GI symptoms.
Relief SystemUse for obesity is not covered.
Canaglu (canagliflozin) — SGLT2 inhibitor
Approval in JapanApproved for type 2 diabetes. Use for obesity is not approved.
Same ingredientNo same-ingredient obesity-indication drug is approved in Japan.
Overseas approvalFDA-approved for type 2 diabetes.
Side effectsUrinary-tract infection, genital infection, dehydration, hypoglycemia, GI symptoms.
Relief SystemUse for obesity is not covered.
Metformin — Biguanide class glucose-lowering drug
Approval in JapanApproved for type 2 diabetes. Use for obesity is not approved.
Same ingredientNo same-ingredient obesity-indication drug is approved in Japan.
Overseas approvalFDA-approved for type 2 diabetes.
Side effectsGI symptoms, vitamin B12 deficiency, lactic acidosis (rare), headache, taste disturbance, hypoglycemia.
Relief SystemUse for obesity is not covered.
Kampo (Bofu-tsusho-san / Boi-ogi-to)
Approval in JapanBoth are approved. Insurance coverage is available for obesity.
NoteAt our clinic these may be provided on a self-pay basis.
Side effectsGI symptoms, liver-function impairment (rare), interstitial pneumonia (rare).
Relief SystemCovered (these are approved medications).

Unapproved medications are obtained through personal importation by partner-clinic physicians, in accordance with MHLW's official procedure. For details, please refer to the MHLW website.

*Based on publicly available information as of March 2025.

Start a free LINE consultation